> Detailanzeige

Gkika, Eleni; Lenz, Stefan; Schimek-Jasch, Tanja; Waller, Cornelius F.; Kremp, Stephanie; Schaefer-Schuler, Andrea; Mix, Michael; Küsters, Andreas; Tosch, Marco; Hehr, Thomas; Eschmann, Susanne Martina; Bultel, Yves-Pierre; Hass, Peter; Fleckenstein, Jochen; Thieme, Alexander Henry; Stockinger, Marcus; Dieckmann, Karin; Miederer, Matthias; Holl, Gabriele; Rischke, Hans Christian; Adebahr, Sonja; König, Jochem; Binder, Harald; Grosu, Anca-Ligia;

Efficacy and Toxicity of Different Chemotherapy Protocols for Concurrent Chemoradiation in Non-Small Cell Lung Cancer—A Secondary Analysis of the PET Plan Trial

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Efficacy and Toxicity of Different Chemotherapy Protocols for Concurrent Chemoradiation in Non-Small Cell Lung Cancer—A Secondary Analysis of the PET Plan Trial
  • Beteiligte: Gkika, Eleni; Lenz, Stefan; Schimek-Jasch, Tanja; Waller, Cornelius F.; Kremp, Stephanie; Schaefer-Schuler, Andrea; Mix, Michael; Küsters, Andreas; Tosch, Marco; Hehr, Thomas; Eschmann, Susanne Martina; Bultel, Yves-Pierre; Hass, Peter; Fleckenstein, Jochen; Thieme, Alexander Henry; Stockinger, Marcus; Dieckmann, Karin; Miederer, Matthias; Holl, Gabriele; Rischke, Hans Christian; Adebahr, Sonja; König, Jochem; Binder, Harald; Grosu, Anca-Ligia;
  • Erschienen: MDPI AG, 2020
  • Erschienen in: Cancers
  • Sprache: Englisch
  • DOI: 10.3390/cancers12113359
  • ISSN: 2072-6694
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>(1) Background: The optimal chemotherapy (CHT) regimen for concurrent chemoradiation (cCRT) is not well defined. In this secondary analysis of the international randomized PET-Plan trial, we evaluate the efficacy of different CHT. (2) Methods: Patients with inoperable NSCLC were randomized at a 1:1 ratio regarding the target volume definition and received isotoxically dose-escalated cCRT using cisplatin 80 mg/m2 (day 1, 22) and vinorelbin 15 mg/m2 (day 1, 8, 22, 29) (P1) or cisplatin 20 mg/m2 (day 1–5, 29–33) and vinorelbin 12.5 mg/m2 (day 1, 8, 15, 29, 36, 43) (P2) or carboplatin AUC1 (day 1–5, 29–33) and vinorelbin 12.5 mg/m2 (day 1, 8, 15, 29, 36, 43) (P3) or other CHT at the treating physician’s discretion. (3) Results: Between 05/2009 and 11/2016, 205 patients were randomized and 172 included in the per-protocol analysis. Patients treated in P1 or P2 had a better overall survival (OS) compared to P3 (p = 0.015, p = 0.01, respectively). Patients treated with carboplatin had a worse OS compared to cisplatin (HR 1.78, p = 0.03), but the difference did not remain significant after adjusting for age, ECOG, cardiac function creatinine and completeness of CHT. (4) Conclusions: Carboplatin doublets show no significant difference compared to cisplatin, after adjusting for possibly relevant factors, probably due to existing selection bias.</jats:p>
  • Zugangsstatus: Freier Zugang